Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. [electronic resource]
Producer: 20080602Description: 560-5 p. digitalISSN:- 1592-8721
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- analysis
- Boronic Acids -- administration & dosage
- Bortezomib
- Disease Progression
- Disease-Free Survival
- Female
- Follow-Up Studies
- Gastrointestinal Diseases -- chemically induced
- Hematologic Diseases -- chemically induced
- Humans
- Karnofsky Performance Status
- Male
- Melphalan -- administration & dosage
- Multiple Myeloma -- drug therapy
- Prednisone -- administration & dosage
- Prognosis
- Pyrazines -- administration & dosage
- Survival Analysis
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.